Clinical Trials on Stage IIIA Merkel Cell Carcinoma AJCC v7

Total 3299 results

Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb; Traws Pharma, Inc.

Completed

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Adenocarcinoma | Non-small Cell Lung Cancer | Stage IV

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
Stanford University

Completed

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

Stage IV Lung Cancer | Metastatic Malignant Neoplasm in the Lung | Non-Small Cell Lung Carcinoma | Malignant Lung Neoplasm

United States
European Organisation for Research and Treatment...

Not yet recruiting

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (ICARS)

NSCLC Stage IV
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
NYU Langone Health

Recruiting

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC (IRRADIATE-Lung)

NSCLC Stage IV

United States
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd.

Unknown

Neo-MASCT Immunotherapy for Advanced NSCLC.

NSCLC Stage IV

China
National Cancer Institute (NCI)

Completed

Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Stage IV Ovarian Germ Cell Tumor | Recurrent Ovarian Germ Cell Tumor | Stage III Testicular Cancer | Recurrent Malignant Testicular Germ Cell Tumor | Recurrent Extragonadal Seminoma | Recurrent Malignant Extragonadal Germ Cell Tumor | Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell... and other conditions

United States
University Health Network, Toronto

Completed

18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

Canada
Dana-Farber Cancer Institute
Celula, Inc.

Terminated

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
VA Office of Research and Development
Oncovir, Inc.

Not yet recruiting

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC (HAITEN-ICI)

Stage IV NSCLC

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
Oncology Institute of Southern Switzerland
Ente Ospedaliero Cantonale, Bellinzona; Clinical Trial Unit Ente Ospedaliero... and other collaborators

Active, not recruiting

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

NSCLC Stage IV

Switzerland
AIO-Studien-gGmbH
AstraZeneca

Withdrawn

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

NSCLC Stage IV

Germany
Amsterdam UMC, location VUmc

Unknown

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

NSCLC, Stage I
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Western Sydney Local Health District
University of Western Sydney

Recruiting

Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

Hepatitis | Lung Cancer, Non-small Cell | Lung Cancer Stage IV

Australia
AstraZeneca

Active, not recruiting

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Extensive-stage Small Cell Lung Cancer

Canada, Germany, Italy, Czechia, Turkey, Bulgaria
Mehrdad Abedi, MD
Amgen

Completed

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Stage IV Adult Lymphoblastic Lymphoma | Contiguous Stage II Adult Lymphoblastic Lymphoma | Noncontiguous Stage II Adult Lymphoblastic Lymphoma | Stage I Adult Lymphoblastic Lymphoma | Stage III Adult Lymphoblastic Lymphoma | Untreated Adult Acute Lymphoblastic Leukemia

United States
Excel Diagnostics and Nuclear Oncology Center

Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)

Neuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Unknown Primary Tumors | Pulmonary Neuroendocrine Neoplasm | Thymus Carcinoid | Neuroendocrine Skin Carcinoma | Neuroendocrine Breast Tumor | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Neoplasm of Ovary

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Recruiting

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Melanoma Stage IV | Melanoma Stage III | Drug Toxicity | Immune-related Adverse Event | Skin Cancer Stage III | Skin Cancer Stage IV | Drug-Induced Colitis

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Active, not recruiting

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
Swedish Lung Cancer Study Group

Recruiting

Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC (MARS)

Quality of Life | Non Small Cell Lung Cancer | Radiotherapy | Stage IV Non-small Cell Lung Cancer

Sweden
University of Chicago
National Cancer Institute (NCI)

Terminated

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States, Saudi Arabia, Puerto Rico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, South Africa
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
William Carson

Completed

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Hepatocellular Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor

United States
Hospital Universitario Virgen Macarena

Recruiting

Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT)

Melanoma Stage III

Spain

Clinical Trials on Stage IIIA Merkel Cell Carcinoma AJCC v7

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations